Related Experiment Video
Updated: Aug 23, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Tolerance of normal human brain to boron neutron capture therapy
J A Coderre1, J W Hopewell, J C Turcotte
1Nuclear Engineering Department, Massachusetts Institute of Technology, 150 Albany Street, Cambridge, MA 02139, USA. coderre@mit.edu
Abstract:
Data from the Harvard-MIT and the BNL Phase I and Phase I/II clinical trials, conducted between 1994 and 1999, have been analyzed and combined, providing the most complete data set yet available on the tolerance of the normal human brain to BPA-mediated boron neutron capture therapy. Both peak (1cm(3)) dose and average whole-brain dose show a steep dose-response relationship using somnolence syndrome as the clinical endpoint. Probit analysis indicates that the doses associated with a 50% incidence for somnolence (ED(50)+/-SE) were 6.2+/-1.0 Gy(w) for average whole-brain dose and 14.1+/-1.8 Gy(w) for peak brain dose.
